Another prospective study of TP53 mutations in cfDNA of 61 high-grade serous ovarian cancer patients demonstrated that patients with high levels of detectable ctDNA (≥0.2 copies/μL), 3 months after completing adjuvant chemotherapy had a significantly higher risk of recurrence of 58.3% compared to 6.7% in patients with low ctDNA levels (<0.2 copies/μL) [21]. This evidence concerns the gene TP53 and ovarian serous adenocarcinoma.